Twitter/X

Intercept is a $500 million philanthropic initiative launched by Nan Ransohoff on…

2026-06-24 · 12:36 UTC ·@nanransohoff ·1 min read

Brief

Intercept is a $500M philanthropic effort launched by Nan Ransohoff on June 24, 2026 to target respiratory infections (common cold, flu) with two product paths: broad-spectrum preventatives and air-cleaning technologies. After convening ~40 experts in 2025, the initiative concluded the obstacles are technical (many mutating strains) and a persistent funding gap; anchor backers include Stripe, Anthropic, The Flu Lab, Foundation OAI, and Jane Street individuals.

Why it matters

Intercept is a $500 million philanthropic initiative launched by Nan Ransohoff on 2026-06-24 to make respiratory infections (common cold, flu) a thing of the past by catalyzing development and deployment of broad-spectrum preventatives and air-cleaning technologies.

Key details

  • Ransohoff cites the scale of the problem: most people will spend 5% of their lives sick from respiratory viruses; these infections kill ~1,000,000 people per year and cost roughly $600 billion annually in lost productivity.
  • After convening ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts in 2025, organizers identified two primary barriers—technical complexity (hundreds of mutating strains across multiple families, now addressable by recent breakthroughs) and chronic underfunding—and named anchor funders including Stripe, Anthropic, The Flu Lab, Foundation OAI, and individuals from Jane Street.
Source evidence

Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past.

We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics.

So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that.

We heard two main reasons:
(1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible.
(2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained).

We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies.

This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot.

We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street.

And, I’m very excited to be building this with @incredutility and the rest of the team.

Nan Ransohoff (@nanransohoff)

interceptfund.substack.com/p…

— https://nitter.net/nanransohoff/status/2069759868656058632#m